BioCardia(BCDA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BCDA BioCardia

已收盘 06-17 16:00:00 EDT

0.9476

+0.0802

+9.25%

盘后0.9199

-0.0277-2.92%

19:53 EDT

最高0.9598	最低0.8300	成交量48.32万
今开0.8560	昨收0.8674	日振幅14.96%
总市值1,078万	流通市值853.80万	总股本1,137万
成交额42.93万	换手率5.36%	流通股本901.02万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":0.9476,"timestamp":1781726400000,"preClose":0.8674,"halted":0,"volume":483206,"hourTrading":{"tag":"盘后","latestPrice":0.9199,"preClose":0.9476,"latestTime":"19:53 EDT","volume":12726,"amount":11681.15224,"timestamp":1781740429328,"change":-0.0277,"changeRate":-0.029232,"amplitude":0.060363},"delay":0,"changeRate":0.09246022596264705,"floatShares":9010150,"shares":11374700,"eps":-0.946888,"marketStatus":"已收盘","change":0.0802,"latestTime":"06-17 16:00:00 EDT","open":0.856,"high":0.9598,"low":0.83,"amount":429332.20336559997,"amplitude":0.149643,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.946888,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781769600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.8674,"preHourTrading":{"tag":"盘前","latestPrice":0.821,"preClose":0.8674,"latestTime":"09:28 EDT","volume":20703,"amount":17221.7139489,"timestamp":1781702886021,"change":-0.0464,"changeRate":-0.053493,"amplitude":0.054646},"postHourTrading":{"tag":"盘后","latestPrice":0.9199,"preClose":0.9476,"latestTime":"19:53 EDT","volume":12726,"amount":11681.15224,"timestamp":1781740429328,"change":-0.0277,"changeRate":-0.029232,"amplitude":0.060363},"volumeRatio":0.53601,"impliedVol":0.046,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCDA/tweets","defaultTab":"tweets","newsList":[{"id":"1198516411","title":"FDA确认Cardiamp HF II研究或支持Cardiamp细胞疗法针对缺血性HFrEF的上市前批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1198516411","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198516411?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:01","pubTimestamp":1780660868,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已确认，Cardiamp HF II临床试验的结果，可能为BioCardia公司旗下Cardiamp细胞疗法用于治疗缺血性心力衰竭伴射血分数降低（HFrEF）的上市前批准（PMA）申请提供支持性数据。这一积极反馈标志着该创新疗法在监管审批路径上的关键进展，为后续正式提交PMA奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102327068","title":"BioCardia宣布日本PMDA咨询记录支持其针对缺血性心力衰竭的Cardiamp细胞疗法规提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1102327068","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102327068?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:01","pubTimestamp":1779969677,"startTime":"0","endTime":"0","summary":"BioCardia公司宣布，其针对缺血性心力衰竭的Cardiamp细胞疗法，已获得日本药品医疗器械综合机构（PMDA）的咨询记录支持，这为后续的正式法规提交与审批铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132654048","title":"BioCardia首季净亏损225.9万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132654048","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132654048?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:15","pubTimestamp":1778847345,"startTime":"0","endTime":"0","summary":"BioCardia最新发布的财报显示，公司第一季度录得净亏损225.9万美元。同期，其运营亏损达到226.6万美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196386789","title":"BioCardia与日本PMDA就Cardiamp临床数据用于支持缺血性心力衰竭监管批准达成共识","url":"https://stock-news.laohu8.com/highlight/detail?id=1196386789","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196386789?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:02","pubTimestamp":1776686542,"startTime":"0","endTime":"0","summary":"BioCardia与日本药品医疗器械综合机构（PMDA）已就Cardiamp疗法临床数据的可接受性达成一致，该数据将用于支持其在缺血性心力衰竭适应症上的监管批准申请。此次共识标志着该疗法在进军日本监管审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193180143","title":"BioCardia申请与FDA会面 探讨Cardiamp®系统治疗缺血性心力衰竭的加速审批路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1193180143","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193180143?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:12","pubTimestamp":1775139168,"startTime":"0","endTime":"0","summary":"BioCardia已正式向美国食品药品监督管理局提交会议请求，旨在商讨其Cardiamp®系统针对缺血性心力衰竭疗法采用加速审批通道的可能性。这一举措标志着公司在推进该创新医疗技术的监管进程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180511815","title":"BioCardia宣布Helix经心内膜输送导管预提交批准方案获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1180511815","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180511815?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:02","pubTimestamp":1773741736,"startTime":"0","endTime":"0","summary":"BioCardia公司近日宣布，其Helix经心内膜输送导管的预提交批准方案已获得美国食品药品监督管理局（FDA）的正式受理。这一进展标志着该创新医疗器械在监管审批流程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111252574","title":"BioCardia就Helix™经心内膜输送导管向FDA提交上市前申请，用于心脏治疗和诊断药物递送","url":"https://stock-news.laohu8.com/highlight/detail?id=1111252574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111252574?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:16","pubTimestamp":1770732975,"startTime":"0","endTime":"0","summary":"BioCardia已向美国食品药品监督管理局（FDA）提交了Helix™经心内膜输送导管的上市前申请。该导管旨在将治疗性和诊断性药物精准递送至心脏靶向区域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609018519","title":"Biocardia, Inc.盘中异动 早盘股价大跌6.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609018519","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609018519?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:41","pubTimestamp":1770388913,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日22时41分，Biocardia, Inc.股票出现异动，股价快速下跌6.44%。Biocardia, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Klotho Neurosciences Inc C/Wts 21/06/2029 、Liminatus Pharma Inc C/Wts 30/04/2030 涨幅较大，Clearmind Medicine Inc.、Liminatus Pharma, Inc.、Aim Immunotech Inc.较为活跃，换手率分别为419.43%、18.51%、15.42%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Cingulate Inc C/Wts 10/12/2026 、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为47.83%、21.54%、18.03%。Biocardia, Inc.公司简介：BioCardia Inc是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020622415497a53b6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020622415497a53b6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0203345920.USD","BK4575","BK4588","BK4585","BK4567","CMI","BK4533","LU0154245756.USD","BK4149","BK4150","LU0154245673.USD","MSC","LU0203347892.USD","BCDA","ARDS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173911177","title":"BioCardia用于缺血性心力衰竭的细胞疗法将正式向日本PMDA进行临床咨询","url":"https://stock-news.laohu8.com/highlight/detail?id=1173911177","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173911177?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:05","pubTimestamp":1765890342,"startTime":"0","endTime":"0","summary":"BioCardia用于缺血性心力衰竭的细胞疗法将正式向日本PMDA进行临床咨询","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516630045","title":"Biocardia, Inc.盘中异动 股价大涨6.97%报2.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630045","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516630045?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:25","pubTimestamp":1741015522,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时25分，Biocardia, Inc.股票出现异动，股价大幅上涨6.97%。截至发稿，该股报2.15美元/股，成交量9683股，换手率0.21%，振幅3.48%。Biocardia, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303232523989a1e26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303232523989a1e26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516013963","title":"Biocardia, Inc.盘中异动 股价大跌5.64%报1.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516013963","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516013963?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:43","pubTimestamp":1740775432,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时43分，Biocardia, Inc.股票出现异动，股价大幅下跌5.64%。截至发稿，该股报1.93美元/股，成交量3.5696万股，换手率0.78%，振幅6.92%。Biocardia, Inc.股票所在的生物技术行业中，整体涨幅为0.76%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301044352abe13c67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301044352abe13c67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514485635","title":"Biocardia, Inc.盘中异动 早盘股价大涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514485635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514485635?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:36","pubTimestamp":1740580581,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时36分，Biocardia, Inc.股票出现异动，股价大幅拉升5.37%。Biocardia, Inc.股票所在的生物技术行业中，整体跌幅为0.19%。其相关个股中，Sab Biotherapeutics Inc C/Wts 22/10/2026 、Immunoprecise Antibodies Ltd.、Channel Therapeutics Corporation涨幅较大，Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为132.66%、99.82%、80.07%，振幅较大的相关个股有Humacyte Inc C/Wts 27/08/2026 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Plus Therapeutics, Inc.，振幅分别为38.41%、27.33%、21.29%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223621abddee1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223621abddee1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514043720","title":"Biocardia, Inc.盘中异动 下午盘大幅下挫5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514043720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514043720?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:24","pubTimestamp":1740511470,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时24分，Biocardia, Inc.股票出现波动，股价快速下挫5.58%。Biocardia, Inc.股票所在的生物技术行业中，整体跌幅为0.17%。其相关个股中，Organovo Holdings, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1972.40%、1168.43%、1000.77%，振幅较大的相关个股有Organovo Holdings, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为241.19%、224.55%、112.90%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226032431abdcc1c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226032431abdcc1c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513783217","title":"Biocardia, Inc.盘中异动 快速下挫5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513783217","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513783217?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:08","pubTimestamp":1740409704,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时08分，Biocardia, Inc.股票出现波动，股价快速下跌5.58%。Biocardia, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为166.64%、73.09%、26.03%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、42.86%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230824abdb16e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230824abdb16e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512722194","title":"Biocardia, Inc.盘中异动 临近收盘股价大跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512722194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512722194?lang=zh_cn&edition=full","pubTime":"2025-02-19 04:50","pubTimestamp":1739911826,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日04时50分，Biocardia, Inc.股票出现波动，股价大幅下跌5.28%。截至发稿，该股报2.69美元/股，成交量3.8454万股，换手率0.84%，振幅5.28%。Biocardia, Inc.股票所在的生物技术行业中，整体涨幅为0.78%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219045026abd3fca4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219045026abd3fca4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511613435","title":"Biocardia, Inc.盘中异动 股价大涨8.46%报2.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511613435","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511613435?lang=zh_cn&edition=full","pubTime":"2025-02-15 01:51","pubTimestamp":1739555503,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日01时51分，Biocardia, Inc.股票出现异动，股价大幅上涨8.46%。Biocardia, Inc.股票所在的生物技术行业中，整体跌幅为0.49%。其相关个股中，Moleculin Biotech, Inc.、Allogene Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为2904.26%、764.93%、598.12%，振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Moleculin Biotech, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为74.35%、71.65%、66.45%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215015143abcf3133&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215015143abcf3133&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511857785","title":"Biocardia, Inc.盘中异动 大幅上涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511857785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511857785?lang=zh_cn&edition=full","pubTime":"2025-02-14 04:49","pubTimestamp":1739479756,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日04时49分，Biocardia, Inc.股票出现波动，股价急速上涨5.32%。Biocardia, Inc.股票所在的生物技术行业中，整体涨幅为1.21%。其相关个股中，Moleculin Biotech, Inc.、Dominari Holdings Inc.、Edesa Biotech, Inc.涨幅较大，Edesa Biotech, Inc.、Moleculin Biotech, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为3285.51%、2315.06%、1269.26%，振幅较大的相关个股有Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为733.31%、95.15%、92.30%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214044916a244f547&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214044916a244f547&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510333496","title":"Biocardia, Inc.盘中异动 股价大涨8.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510333496","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510333496?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:53","pubTimestamp":1739285584,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时53分，Biocardia, Inc.股票出现异动，股价急速拉升8.26%。Biocardia, Inc.股票所在的生物技术行业中，整体跌幅为1.29%。其相关个股中，Ocean Biomedical, Inc.、Dominari Holdings Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2390.52%、658.51%、291.88%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为45.29%、33.04%、33.02%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211225304961f4bfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211225304961f4bfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509874270","title":"Biocardia, Inc.盘中异动 股价大涨6.12%报2.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509874270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509874270?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:36","pubTimestamp":1738939018,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日22时36分，Biocardia, Inc.股票出现波动，股价急速上涨6.12%。截至发稿，该股报2.60美元/股，成交量4587股，换手率0.10%，振幅0.00%。Biocardia, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223659abc62bfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223659abc62bfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509491280","title":"Biocardia, Inc.盘中异动 急速上涨6.23%报2.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509491280","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509491280?lang=zh_cn&edition=full","pubTime":"2025-02-05 23:14","pubTimestamp":1738768491,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日23时14分，Biocardia, Inc.股票出现波动，股价急速拉升6.23%。截至发稿，该股报2.73美元/股，成交量9694股，换手率0.21%，振幅6.23%。Biocardia, Inc.股票所在的生物技术行业中，整体涨幅为1.15%。Biocardia, Inc.公司简介：BioCardia Inc 是一家临床阶段公司，开发细胞和细胞衍生疗法，用于治疗未满足医疗需求的心血管和肺部疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205231451a23a854d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205231451a23a854d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":0.009},{"period":"1month","weight":-0.1412},{"period":"3month","weight":-0.2948},{"period":"6month","weight":-0.3223},{"period":"1year","weight":-0.6229},{"period":"ytd","weight":-0.3061}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biocardia, Inc.于1994年1月12日在特拉华州注册成立。该公司是一家临床阶段的公司，开发用于心血管和肺部疾病的细胞及细胞衍生疗法。其CardiAMP自体单个核细胞治疗平台正在推进用于缺血性心力衰竭和难治性心绞痛，而其同种异体间充质干细胞治疗平台正在开发用于缺血性炎症性心力衰竭。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.066663},{"month":2,"riseRate":0.5,"avgChangeRate":-0.017269},{"month":3,"riseRate":0.25,"avgChangeRate":-0.022375},{"month":4,"riseRate":0.375,"avgChangeRate":0.007226},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.09523},{"month":6,"riseRate":0.222222,"avgChangeRate":-0.050292},{"month":7,"riseRate":0.5,"avgChangeRate":-0.016411},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102769},{"month":9,"riseRate":0.375,"avgChangeRate":0.008782},{"month":10,"riseRate":0.375,"avgChangeRate":-0.049332},{"month":11,"riseRate":0.5,"avgChangeRate":0.042585},{"month":12,"riseRate":0.375,"avgChangeRate":-0.012187}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioCardia(BCDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioCardia(BCDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}